57 results
8-K
EX-99.2
ABOS
Acumen Pharmaceuticals Inc
14 May 24
Acumen Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Highlights
7:35am
May Provide Meaningful Cognitive Efficacy and Improved Safety 9 Monomers Oligomers Protofibrils Fibrils Plaques Soluble Amyloid Insoluble Amyloid … disease FDA End of Phase 2 meeting in 4Q 2023 sabirnetug IgG2 Rationally Designed for Improved Efficacy & Safety Large Pharma Discovery Encouraging FDA
8-K
EX-99.1
ABOS
Acumen Pharmaceuticals Inc
14 May 24
Acumen Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Highlights
7:35am
on the initiation of ALTITUDE-AD, our Phase 2 study investigating the efficacy and safety of sabirnetug for the treatment of early AD. We announced … to investigate the clinical efficacy and safety of sabirnetug for the treatment of early AD.
In April 2024, the Company presented biomarker, safety and target
8-K
EX-99.1
8fuqlb5prlljyt220
26 Mar 24
Results of Operations and Financial Condition
7:42am
8-K
EX-99.1
l3uigv1z044wjt61iyv
19 Mar 24
Corporate Presentation March 2024 1
8:05am
8-K
EX-99.1
8pvj0 kbb6d73ewu
12 Jan 24
Corporate Presentation January 2024 1
8:42am
8-K
EX-99.1
ealta ld8dioi
8 Jan 24
Regulation FD Disclosure
8:33am
8-K
EX-99.1
nxvbbstu7s8
4 Dec 23
Corporate Presentation December 2023 1
7:45am
8-K
EX-99.1
7xo7ide zgl
13 Nov 23
Corporate Presentation November 2023 1
5:10pm
8-K
EX-99.1
cz15yp
13 Nov 23
Acumen Pharmaceuticals Reports Third Quarter 2023 Financial Results and Business Highlights
7:20am
8-K
EX-99.2
nh56dssk gky8slzqwhv
8 Aug 23
Acumen Pharmaceuticals Reports Second Quarter 2023 Financial Results and Business Highlights
7:33am
8-K
EX-99.1
c031b kq5
8 Aug 23
Acumen Pharmaceuticals Reports Second Quarter 2023 Financial Results and Business Highlights
7:33am
424B5
h5migv tn8lgtg
20 Jul 23
Prospectus supplement for primary offering
4:11pm
424B5
af83hppi cj
17 Jul 23
Prospectus supplement for primary offering
4:49pm